<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2133">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133388</url>
  </required_header>
  <id_info>
    <org_study_id>β thalassemia gene mutation</org_study_id>
    <nct_id>NCT05133388</nct_id>
  </id_info>
  <brief_title>The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients</brief_title>
  <official_title>The Prevelence of HBB c.93-21 G-A Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of&#xD;
           the IVS I-110 (G&gt;A) [HBB:c.93-21G˃A] mutation.&#xD;
&#xD;
        -  To detect the prevelence of the mutation among Assiut University Hospital patients.&#xD;
&#xD;
        -  Phenotype/genotype correlation of the mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The β-thalassaemias result from over 300 gene mutations (Kurtoğlu A,et al 2016)&#xD;
&#xD;
        -  These mutations are regionally specific and the spectrum of mutations has been&#xD;
           determined for most at-risk populations. The strategy for identifying β-thalassaemia&#xD;
           mutations is usually based on knowledge of the common mutations in the ethnic group of&#xD;
           the individual being screened (Old JM, 2007).&#xD;
&#xD;
      The β globin gene mutation [HBB:c.93-21G˃A] or IVS I-110 (G&gt;A) is the most common β globin&#xD;
      gene mutation in the Mediterranean region (Old JM, 2007). . There is no consensus about the %&#xD;
      of the mutation among β thalassemic patients in Egypt [has been reported (25.8%) by&#xD;
      El-Gawhary et al. 2007, (33.75%) by Soliman et al. 2010, (48%) by El-Shanshory et al. 2014,&#xD;
      (22%) by Elmezayen et al. 2015 and (34%) by Elhalfawy et al. 2017].&#xD;
&#xD;
      According to the HbVar site, it represents 33% of the β globin gene mutations in the&#xD;
      Egyptians. 28.5% according to Henderson S ,et al 2009 .&#xD;
&#xD;
        -  The mechanism of this mutation depends on formation of a new splicing site resulting in&#xD;
           80% abnormal spliced mRNA and 20% normal mRNA .&#xD;
&#xD;
        -  The molecular characterization of the globin gene mutation is necessary for definite&#xD;
           diagnosis, genetic counseling, and in prenatal diagnosis.&#xD;
&#xD;
        -  The amplification-refractory mutation system (ARMS) is a simple method for detecting any&#xD;
           mutation involving single base changes or small deletions.&#xD;
&#xD;
        -  The DNA is analyzed after amplification by PCR for Detection of point mutation IVS I-110&#xD;
           (G&gt;A) by Using primer pairs that only amplify individual alleles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Introduction of arms pcr in diagnosis .</measure>
    <time_frame>2 years</time_frame>
    <description>To introduce the ARMS PCR as a cheap and simple DNA diagnostic tool for any point mutation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Database initation .</measure>
    <time_frame>2 years</time_frame>
    <description>Initiating database of haemoglobinopathesis by registering data.</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Beta-Thalassemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ARMS PCR</intervention_name>
    <description>ARMS PCR using primer pairs that only amplify individual alleles</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Assiut University Hospitals patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  β thalassemia (suspected &amp; clinically diagnosed cases)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias&#xD;
             other than thalassemia, other types of thalassemia and Hb variants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ola Afifi</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amira Saber</last_name>
    <phone>01063954423</phone>
    <email>amirasaberh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Samir</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Assiut University</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamed Samir</last_name>
      <phone>01015484723</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Henderson S, Timbs A, McCarthy J, Gallienne A, Van Mourik M, Masters G, May A, Khalil MS, Schuh A, Old J. Incidence of haemoglobinopathies in various populations - the impact of immigration. Clin Biochem. 2009 Dec;42(18):1745-56. doi: 10.1016/j.clinbiochem.2009.05.012. Epub 2009 Jun 1.</citation>
    <PMID>19497317</PMID>
  </reference>
  <reference>
    <citation>Old JM. Screening and genetic diagnosis of haemoglobinopathies. Scand J Clin Lab Invest. 2007;67(1):71-86. Review.</citation>
    <PMID>17365985</PMID>
  </reference>
  <reference>
    <citation>El-Gawhary S, El-Shafie S, Niazi M, Aziz M, El-Beshlawy A. Study of beta-Thalassemia mutations using the polymerase chain reaction-amplification refractory mutation system and direct DNA sequencing techniques in a group of Egyptian Thalassemia patients. Hemoglobin. 2007;31(1):63-9.</citation>
    <PMID>17365006</PMID>
  </reference>
  <reference>
    <citation>Soliman OE, Yahia S, Shouma A, Shafiek HK, Fouda AE, Azzam H, Abousamra NK, Mahfouz R, Goda EF, El-Sharawy SA. Reverse hybridization StripAssay detection of beta-thalassemia mutations in northeast Egypt. Hematology. 2010 Jun;15(3):182-6. doi: 10.1179/102453310X12583347010214.</citation>
    <PMID>20557680</PMID>
  </reference>
  <reference>
    <citation>El-Shanshory M, Hagag A, Shebl S, Badria I, Abd Elhameed A, Abd El-Bar E, Al-Tonbary Y, Mansour A, Hassab H, Hamdy M, Alfy M, Sherief L, Sharaf E. Spectrum of Beta Globin Gene Mutations in Egyptian Children with β-Thalassemia. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014071. doi: 10.4084/MJHID.2014.071. eCollection 2014.</citation>
    <PMID>25408857</PMID>
  </reference>
  <reference>
    <citation>Elmezayen AD, Kotb SM, Sadek NA, Abdalla EM. β-Globin Mutations in Egyptian Patients With β-Thalassemia. Lab Med. 2015 Winter;46(1):8-13. doi: 10.1309/LM1AYKG6VE8MLPHG.</citation>
    <PMID>25617386</PMID>
  </reference>
  <reference>
    <citation>Kurtoğlu A, Karakuş V, Erkal Ö, Kurtoğlu E. β-Thalassemia gene mutations in Antalya, Turkey: results from a single centre study. Hemoglobin. 2016 Nov;40(6):392-395. doi: 10.1080/03630269.2016.1256818. Epub 2017 Mar 3.</citation>
    <PMID>28276871</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amira Saber Hamed Ahmed</investigator_full_name>
    <investigator_title>ASHAhmed</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

